[Adalimumab in the treatment of rheumatoid arthritis].
Bendtzen
Klaus
K
H:S Rigshospitalet, Finsencentret, Institut for Inflammationsforskning, København. kben@mail.dk
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D012449:Safety; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab